Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
Recruiting now · Phase 1
Conditions studied: Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
In brief
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Key facts
- Study ID
- NCT05490888
- Run by
- PharmaIN
- People needed
- 74
- Starts
- 2022-01-03
- Expected to finish
- 2026-06-30
- Last updated by the study team
- 2025-09-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Liver Health — Chandler, Arizona, United States (enrolling)
- Southern California Research Center — Coronado, California, United States (enrolling)
- Tandem Clinical Research — Marrero, Louisiana, United States (enrolling)
- Mayo Clinic — Rochester, Minnesota, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (enrolling)
- Methodist Health System, Dallas Medical Center — Dallas, Texas, United States (enrolling)
- VA North Texas Healthcare System — Dallas, Texas, United States (enrolling)
- Texas Liver Institute — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.